Ken Hallenbeck earned a Ph.D. in pharmaceutical sciences from the University of California, San Francisco, and now is an early drug-discovery researcher. He serves on the board of directors of ReImagine Science and is the life sciences lead at TerraPrime.
Articles by Ken Hallenbeck
A downside to liposome drug delivery?
March 7, 2023
When researchers injected mice with liposomes, they found that white blood cells showed signs of stress, leading to decreased ability to create immune cell types.
What is better for your career than a publication? A preprint.
Sept. 22, 2022
“Depositing a paper outside of an academic journal allows an author to start promoting the work immediately,” Ken Hallenbeck writes.
It is finally time for post-publication review
Feb. 3, 2022
The internet has rewritten the rules of print publishing over the last three decades. Why hasn’t it had the same impact on the discussion that follows?
What’s growing in your mouth might change with your health
Dec. 21, 2021
A recent paper in the journal Molecular & Cellular Proteomics takes a tech-enabled deep dive into dental plaques.
Challenging science stereotypes with a video game
July 7, 2021
Imagine a digital game set in a lab that creates a research experience accessible to all and populated by all.
The evolution of proteins from mysteries to medicines
Feb. 27, 2021
An essay in observance of National Protein Day.
Life in the Lab
Time for a new model of data disclosure?
July 15, 2020
Ken Hallenbeck asserts that a flood of scientific papers related to the pandemic provides an opportunity to review core assumptions of the modern publication model.